SCHEMBL30052312

SCHEMBL30052312

CC[C@H](C)[C@H](NC(=O)[C@@H](N)C(C)C)C(=O)N1CCC[C@H]1C(=O)O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ XIAP P98170 1/20 0.56
▸ KMT2A Q03164 1/20 0.51
▸ L3MBTL1 Q9Y468 1/20 0.51
▸ ACE P12821 7/20 0.48
▸ REN P00797 4/20 0.48
▸ KDM4E B2RXH2 1/20 0.48
▸ F2 P00734 1/20 0.48
▸ LMNA P02545 1/20 0.48
▸ LTA4H P09960 1/20 0.48
▸ MAPT P10636 1/20 0.48
▸ PEPD P12955 1/20 0.48
▸ ALOX15 P16050 1/20 0.48
▸ PTGS1 P23219 1/20 0.48
▸ HTR2A P28223 1/20 0.48
▸ PTGS2 P35354 1/20 0.48
▸ HRH1 P35367 1/20 0.48
▸ THPO P40225 1/20 0.48
▸ PMP22 Q01453 1/20 0.48
▸ HSD17B10 Q99714 1/20 0.48
▸ ACE2 Q9BYF1 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30051744 0.94 XIAP (0.54) XIAPKMT2AL3MBTL1ACEREN
SCHEMBL29390805 0.93 XIAP (0.57) XIAPKMT2AL3MBTL1ACEREN
SCHEMBL30051254 0.91 XIAP (0.53) XIAPKMT2AL3MBTL1ACEREN
SCHEMBL31202564 0.91 XIAP (0.55) XIAPKMT2AL3MBTL1ACEREN
SCHEMBL29615598 0.91 XIAP (0.55) XIAPKMT2AL3MBTL1ACEREN
SCHEMBL23260256 0.91 XIAP (0.55) XIAPKMT2AL3MBTL1ACEREN
SCHEMBL31202557 0.91 XIAP (0.55) XIAPKMT2AL3MBTL1ACEREN
SCHEMBL30053268 0.89 ACE (0.50) XIAPKMT2AACERENKDM4E
SCHEMBL30051521 0.86 KMT2A (0.49) XIAPKMT2AL3MBTL1ACEREN
SCHEMBL30744250 0.85 XIAP (0.51) XIAPKMT2AL3MBTL1ACEREN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12622975-B2 Peptide-conjugated prodrugs BRANDEIS UNIVERSITY (US) 2026-05-12 — — US disclosed
US-20220387610-A1 PEPTIDE-CONJUGATED PRODRUGS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2022-12-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12622975-B2 Peptide-conjugated prodrugs PEPD, PAM, VIP XIAP 4043/4885KMT2A 1801/4885L3MBTL1 184/4885
US-20220387610-A1 PEPTIDE-CONJUGATED PRODRUGS VIP, DNPEP, PEPD XIAP 2121/4885KMT2A 4547/4885L3MBTL1 811/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback